Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Study Details
Study Description
Brief Summary
RATIONALE: Monoclonal antibodies, such as alemtuzumab, can find cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Giving chemotherapy drugs, such as busulfan and cyclophosphamide, before a donor stem cell transplant helps stop the growth of cancer cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving tacrolimus and methotrexate after the transplant may stop this from happening.
PURPOSE: This phase I/II trial is studying the best dose of alemtuzumab when given together with busulfan and cyclophosphamide followed by a donor stem cell transplant and to see how well it works in treating patients with hematologic cancer.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 1/Phase 2 |
Detailed Description
OBJECTIVES:
Primary
- Identify the lowest dose of alemtuzumab that is associated with day 180 transplant-related mortality ≤ 45%.
Secondary
-
Determine the incidence of life-threatening infection in patients receiving this treatment.
-
Determine the incidence of grades III-IV acute graft-vs-host disease (GVHD) in patients receiving this treatment.
-
Determine the survival at 1 year in patients receiving this treatment.
-
Determine the incidence of disease relapse at 1 year in patients receiving this treatment.
-
Determine the incidence of extensive chronic GVHD at 1 year in patients receiving this treatment.
-
Determine the incidence of graft failure at day 100 in patients receiving this treatment.
OUTLINE:
-
Chemotherapy: Patients receive alemtuzumab IV over 2 hours on days -10 to -6, busulfan IV over 3 hours on days -7 to -4, and cyclophosphamide IV on days -3 and -2.
-
Peripheral blood stem cell (PBSC) transplantation: Patients undergo allogeneic filgrastim (G-CSF)-mobilized PBSC transplantation on day 0.
-
Graft-vs-host disease prophylaxis: Patients receive tacrolimus IV continuously or orally twice daily on days -1 to 50 and methotrexate IV on days 1, 3, 6, and 11.
After completion of study therapy, patients are followed periodically.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Alemtuzumab Alemtuzumab given together with busulfan and cyclophosphamide followed by a donor stem cell transplant. |
Biological: alemtuzumab
Drug: busulfan
Drug: cyclophosphamide
Drug: methotrexate
Drug: tacrolimus
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
|
Outcome Measures
Primary Outcome Measures
- Lowest Dose of Alemtuzumab Associated With Transplant-related Mortality [Up to day 180]
Lowest dose of alemtuzumab associated with transplant-related mortality at day 180
Secondary Outcome Measures
- Life-threatening Infection [Up to 180 days]
- Grades III-IV Acute Graft-vs-host Disease (GVHD) [Up to 100 days]
- Overall Survival [Up to 1 year]
Count of surviving participants at 1 year
- Disease Relapse [Up to 1 year]
Count of participants with disease relapse at 1 year
- Extensive Chronic GVHD [Up to 1 year]
Count of participants with extensive chronic GVHD at 1 year
- Graft Failure [Up to day 100]
Count of participants with graft failure at day 100
Eligibility Criteria
Criteria
DISEASE CHARACTERISTICS:
-
Confirmed diagnosis of one of the following:
-
Primary acute myeloid leukemia (AML) meeting any of the following criteria:
-
First complete remission (CR; defined as < 5% blasts in marrow) with high-risk features as defined by failure to achieve remission by day 21 after induction chemotherapy, or the presence of chromosomal abnormalities involving any of the following:
-
-5/del(5q)
-
-7/del(7q)
-
Inversion 3q
-
Abnormalities of 11q23, 20q, 21q, del(9q),
-
Translocation 6;9
-
Translocation 9;22
-
Abnormalities of 17p
-
Complex karyotype with ≥ 3 abnormalities
-
Second CR or subsequent in remission
-
Refractory or relapsed disease
-
Secondary AML in remission or relapse
-
Chronic myelogenous leukemia (CML) in accelerated or blast phase meeting the following criteria:
-
Accelerated phase is defined by any one of the following:
-
Blasts 10% to 19% of peripheral blood white cells or bone marrow cells
-
Peripheral blood basophils ≥ 20%
-
Persistent thrombocytopenia (< 100,000/mm³) unrelated to therapy, or persistent thrombocytosis (> 1,000,000/mm³) unresponsive to therapy
-
Increasing spleen size and increasing WBC count unresponsive to therapy
-
Cytogenetic evidence of clonal evolution (i.e., the appearance of an additional genetic abnormality that was not present in the initial specimen at the time of diagnosis of chronic phase CML)
-
Blast phase is defined by any of the following:
-
Blasts ≥ 20% of peripheral blood white cells or bone marrow cells
-
Extramedullary blast proliferation
-
Large foci or clusters of blasts in bone marrow biopsy
-
Primary myelodysplastic syndromes (MDS) with an IPSS score > 1.5
-
Secondary MDS with any IPSS score
-
Primary acute lymphoblastic leukemia meeting any of the following criteria:
-
First CR (< 5% blasts in marrow) with high-risk features as defined by 1 of the following:
-
Failure to achieve remission after first induction chemotherapy
-
Presence of chromosomal abnormalities including hypodiploidy or abnormalities of 11q23 or translocation 9;22
-
Second CR or subsequent in remission
-
Refractory or relapsed disease
-
No patients for whom a suitable HLA genotypically identical sibling or fully matched HLA-A, -B, -C, and -DRB1 unrelated donor is available
-
No active CNS involvement with disease
-
Donors must meet the following criteria:
-
Unrelated volunteer donors who are mismatched for more than one HLA-class I alleles or antigens or for one HLA-class I antigen, but matched by high-resolution typing at HLA-DRB1 and -DQB1, OR who are mismatched for one or more HLA-class II alleles or antigens, but matched by high-resolution typing at HLA-A, -B, and -C
-
No two-antigen mismatch at a single HLA-A, -B, or -C locus
-
No mismatching of class I and class II HLA
-
Matching must be based on results of high-resolution typing at HLA-A, -B, -C, - DRB1, and -DQB1
PATIENT CHARACTERISTICS:
-
Karnofsky performance status 50-100%
-
No symptomatic coronary artery disease or symptomatic congestive heart failure
-
No hepatic disease with transaminases or bilirubin > 2 times upper limit of normal except for isolated hyperbilirubinemia attributed to Gilbert's syndrome
-
No severe hypoxemia with room air P_AO_2 < 70, supplemental oxygen-dependence, or DLCO < 60% predicted
-
No impaired renal function with creatinine > 2 times upper limit of normal or creatinine clearance < 50% normal
-
Not HIV seropositive
-
Not pregnant or breast-feeding
-
Fertile patients must use effective contraception
-
No active infections that are untreated or failing to respond to appropriate therapy
PRIOR CONCURRENT THERAPY:
Inclusion criteria:
- See Disease Characteristics
Exclusion criteria:
- Prior allogeneic or autologous bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation using a high-dose total-body irradiation regimen
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Fred Hutchinson Cancer Research Center | Seattle | Washington | United States | 98104-1024 |
2 | Seattle Cancer Care Alliance | Seattle | Washington | United States | 98109-1023 |
Sponsors and Collaborators
- Fred Hutchinson Cancer Center
- National Cancer Institute (NCI)
Investigators
- Principal Investigator: Ann E. Woolfrey, MD, Fred Hutchinson Cancer Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 1981.00
- P30CA015704
- FHCRC-1981.00
- CDR0000574145
Study Results
Participant Flow
Recruitment Details | |
---|---|
Pre-assignment Detail |
Arm/Group Title | Alemtuzumab |
---|---|
Arm/Group Description | Alemtuzumab given together with busulfan and cyclophosphamide followed by a donor stem cell transplant. alemtuzumab busulfan cyclophosphamide methotrexate tacrolimus allogeneic hematopoietic stem cell transplantation peripheral blood stem cell transplantation |
Period Title: Overall Study | |
STARTED | 1 |
COMPLETED | 1 |
NOT COMPLETED | 0 |
Baseline Characteristics
Arm/Group Title | Alemtuzumab |
---|---|
Arm/Group Description | Alemtuzumab given together with busulfan and cyclophosphamide followed by a donor stem cell transplant. alemtuzumab busulfan cyclophosphamide methotrexate tacrolimus allogeneic hematopoietic stem cell transplantation peripheral blood stem cell transplantation |
Overall Participants | 1 |
Age (years) [Median (Full Range) ] | |
Median (Full Range) [years] |
47
|
Sex: Female, Male (Count of Participants) | |
Female |
0
0%
|
Male |
1
100%
|
Outcome Measures
Title | Lowest Dose of Alemtuzumab Associated With Transplant-related Mortality |
---|---|
Description | Lowest dose of alemtuzumab associated with transplant-related mortality at day 180 |
Time Frame | Up to day 180 |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Alemtuzumab |
---|---|
Arm/Group Description | Alemtuzumab given together with busulfan and cyclophosphamide followed by a donor stem cell transplant. alemtuzumab busulfan cyclophosphamide methotrexate tacrolimus allogeneic hematopoietic stem cell transplantation peripheral blood stem cell transplantation |
Measure Participants | 1 |
Number [mg total dose] |
40
|
Title | Life-threatening Infection |
---|---|
Description | |
Time Frame | Up to 180 days |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Alemtuzumab |
---|---|
Arm/Group Description | Alemtuzumab given together with busulfan and cyclophosphamide followed by a donor stem cell transplant. alemtuzumab busulfan cyclophosphamide methotrexate tacrolimus allogeneic hematopoietic stem cell transplantation peripheral blood stem cell transplantation |
Measure Participants | 1 |
Count of Participants [Participants] |
0
0%
|
Title | Grades III-IV Acute Graft-vs-host Disease (GVHD) |
---|---|
Description | |
Time Frame | Up to 100 days |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Alemtuzumab |
---|---|
Arm/Group Description | Alemtuzumab given together with busulfan and cyclophosphamide followed by a donor stem cell transplant. alemtuzumab busulfan cyclophosphamide methotrexate tacrolimus allogeneic hematopoietic stem cell transplantation peripheral blood stem cell transplantation |
Measure Participants | 1 |
Count of Participants [Participants] |
0
0%
|
Title | Overall Survival |
---|---|
Description | Count of surviving participants at 1 year |
Time Frame | Up to 1 year |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Alemtuzumab |
---|---|
Arm/Group Description | Alemtuzumab given together with busulfan and cyclophosphamide followed by a donor stem cell transplant. alemtuzumab busulfan cyclophosphamide methotrexate tacrolimus allogeneic hematopoietic stem cell transplantation peripheral blood stem cell transplantation |
Measure Participants | 1 |
Count of Participants [Participants] |
1
100%
|
Title | Disease Relapse |
---|---|
Description | Count of participants with disease relapse at 1 year |
Time Frame | Up to 1 year |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Alemtuzumab |
---|---|
Arm/Group Description | Alemtuzumab given together with busulfan and cyclophosphamide followed by a donor stem cell transplant. alemtuzumab busulfan cyclophosphamide methotrexate tacrolimus allogeneic hematopoietic stem cell transplantation peripheral blood stem cell transplantation |
Measure Participants | 1 |
Count of Participants [Participants] |
0
0%
|
Title | Extensive Chronic GVHD |
---|---|
Description | Count of participants with extensive chronic GVHD at 1 year |
Time Frame | Up to 1 year |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Alemtuzumab |
---|---|
Arm/Group Description | Alemtuzumab given together with busulfan and cyclophosphamide followed by a donor stem cell transplant. alemtuzumab busulfan cyclophosphamide methotrexate tacrolimus allogeneic hematopoietic stem cell transplantation peripheral blood stem cell transplantation |
Measure Participants | 1 |
Count of Participants [Participants] |
1
100%
|
Title | Graft Failure |
---|---|
Description | Count of participants with graft failure at day 100 |
Time Frame | Up to day 100 |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Alemtuzumab |
---|---|
Arm/Group Description | Alemtuzumab given together with busulfan and cyclophosphamide followed by a donor stem cell transplant. alemtuzumab busulfan cyclophosphamide methotrexate tacrolimus allogeneic hematopoietic stem cell transplantation peripheral blood stem cell transplantation |
Measure Participants | 1 |
Count of Participants [Participants] |
0
0%
|
Adverse Events
Time Frame | ||
---|---|---|
Adverse Event Reporting Description | ||
Arm/Group Title | Alemtuzumab | |
Arm/Group Description | Alemtuzumab given together with busulfan and cyclophosphamide followed by a donor stem cell transplant. alemtuzumab busulfan cyclophosphamide methotrexate tacrolimus allogeneic hematopoietic stem cell transplantation peripheral blood stem cell transplantation | |
All Cause Mortality |
||
Alemtuzumab | ||
Affected / at Risk (%) | # Events | |
Total | / (NaN) | |
Serious Adverse Events |
||
Alemtuzumab | ||
Affected / at Risk (%) | # Events | |
Total | 0/1 (0%) | |
Other (Not Including Serious) Adverse Events |
||
Alemtuzumab | ||
Affected / at Risk (%) | # Events | |
Total | 0/1 (0%) |
Limitations/Caveats
More Information
Certain Agreements
All Principal Investigators ARE employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
Name/Title | Ann Woolfrey, MD |
---|---|
Organization | Fred Hutchinson Cancer Research Center |
Phone | 206-667-4453 |
awoolfre@fredhutch.org |
- 1981.00
- P30CA015704
- FHCRC-1981.00
- CDR0000574145